Case report
Study theme · illustration
Case report: an individual observation, not an estimate of how well the treatment works for other patients.

Who was studied?

One patient with chemotherapy-refractory MSS/pMMR metastatic colorectal cancer.

What does the publication report?

A complete response with progression-free survival exceeding two years was reported at the published follow-up.

Safety findings

Grade 1 fatigue was reported; no other significant adverse reactions were described in the abstract.

How should we interpret it?

A single patient cannot establish efficacy or predict an individual outcome. Prior and concurrent treatments limit attribution.

Read the original source

This independently written summary was checked against the publicly available abstract. Selected figures, where included, are checked against the full publication. This is not a full-paper translation or a clinical recommendation.

PD-1 inhibitor combined with radiotherapy and GM-CSF in MSS/pMMR metastatic colon cancer: a case report · DOI: 10.3389/fonc.2023.1078915 · PMID: 37188188

Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.